Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 237

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Open access
Dimopoulos, Meletios A, Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria-Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B, Gupta, Neeraj, Labotka, Richard, Rajkumar, S Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Spencer, Andrew, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araújo, Sérgio, Gregora, Evzen, Hajek, Roman, Maisnar, Vladimir, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Moreau, Philippe, Blau, Igor, Goldschmidt, Hartmut, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Röllig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illés, Árpád, Egyed, Miklós, Borbényi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Gay, Francesca, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Iida, Shinsuke, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Min, Chang Ki, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Zweegman, Sonja, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Schjesvold, Fredrik, Waage, Anders, Haukås, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Álvarez Rivas, Miguel Angel, De Arriba de La Fuente, Felipe, González Montes, Yolanda, Martin Sanchez, Jesus, Mateos, Maria Victoria, Oriol Rocafiguera, Albert, Rosinol, Laura, San Miguel, Jesús, Pérez de Oteyza, Jaime, Encinas, Cristina, Alegre-Amor, Adrian, López-Guía, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Hveding Blimark, Cecile, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Na Nakorn, Thanyaphong, Prayongratana, Kannadit, Beksac, Meral, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Kaiser, Martin, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, Janakiram, Murali · 2019 · The Lancet

Abstract

BACKGROUND Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT. METHODS The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study took place in 167 clinical or hospital sites in 30 countries in Europe, the Middle East, Africa, Asia, and North and South America. Eligible participants were adults with a confirmed diagnosis of symptomatic multiple myeloma according to International Myeloma Working Group criteria who had achieved at least a partial response after undergoing standard-of-care induction therapy followed by high-dose melphalan (200 mg/m2) conditioning and single ASCT within 12 months of diagnosis. Patients were randomly assigned in a 3:2 ratio to oral ixazomib or matching placebo on days 1, 8, and 15 in 28-day cycles for 2 years following induction, high-dose therapy, and transplantation. The initial 3 mg dose was increased to 4 mg from cycle 5 if tolerated during cycles 1-4. Randomisation was stratified by induction regimen, pre-induction disease stage, and response post-transplantation. The primary endpoint was progression-free survival (PFS) by intention-to-treat analysis. Safety was assessed in all patients who received at least one dose of ixazomib or placebo, according to treatment actually received. This trial is registered with ClinicalTrials.gov, number NCT02181413, and follow-up is ongoing. FINDINGS Between July 31, 2014, and March 14, 2016, 656 patients were enrolled and randomly assigned to receive ixazomib maintenance therapy (n=395) or placebo (n=261). With a median follow-up of 31 months (IQR 27·3-35·7), we observed a 28% reduction in the risk of progression or death with ixazomib versus placebo (median PFS 26·5 months [95% CI 23·7-33·8] vs 21·3 months [18·0-24·7]; hazard ratio 0·72, 95% CI 0·58-0·89; p=0·0023). No increase in second malignancies was noted with ixazomib therapy (12 [3%] patients) compared with placebo (eight [3%] patients) at the time of this analysis. 108 (27%) of 394 patients in the ixazomib group and 51 (20%) of 259 patients in the placebo group experienced serious adverse events. During the treatment period, one patient died in the ixazomib group and none died in the placebo group. INTERPRETATION Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma. FUNDING Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)33003-4

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 19

  1. Palumbo, 2012, Continuous lenalidomide treatment for newly diagnosed multiple myeloma, N Engl J Med, 366, 1759, 10.1056/NEJMoa1112704 · DOI · Paper page
  2. Sonneveld, 2012, Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial, J Clin Oncol, 30, 2946, 10.1200/JCO.2011.39.6820 · DOI · Paper page
  3. Isoda, 2018, Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial, Int J Hematol, 108, 39, 10.1007/s12185-018-2448-9 · DOI
  4. Gupta, 2017, Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma: clinical and model-based analyses, Target Oncol, 12, 643, 10.1007/s11523-017-0524-3 · DOI
  5. Rajkumar, 2017, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, 117, 4691, 10.1182/blood-2010-10-299487 · DOI · Paper page
  6. O'Brien, 1979, A multiple testing procedure for clinical trials, Biometrics, 35, 549, 10.2307/2530245 · DOI · Paper page
  7. Attal, 1996, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome, N Engl J Med, 335, 91, 10.1056/NEJM199607113350204 · DOI · Paper page
  8. Blade, 2003, High-dose therapy in multiple myeloma, Blood, 102, 3469
  9. 2001, Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients, Br J Haematol, 113, 1020, 10.1046/j.1365-2141.2001.02857.x · DOI · Paper page
  10. Berenson, 2002, Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients, Blood, 99, 3163, 10.1182/blood.V99.9.3163 · DOI · Paper page
  11. Attal, 2006, Maintenance therapy with thalidomide improves survival in patients with multiple myeloma, Blood, 108, 3289, 10.1182/blood-2006-05-022962 · DOI · Paper page
  12. Spencer, 2009, Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure, J Clin Oncol, 27, 1788, 10.1200/JCO.2008.18.8573 · DOI · Paper page
  13. Sengsayadeth, 2017, Posttransplant maintenance therapy in multiple myeloma: the changing landscape, Blood Cancer J, 7, e545, 10.1038/bcj.2017.23 · DOI
  14. Moreau, 2017, Blood, 130, 2021
  15. Gay, 2018, Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis, JAMA Oncol, 4, 1389, 10.1001/jamaoncol.2018.2961 · DOI
  16. Gupta, 2018, Model-informed drug development for ixazomib, an oral proteasome inhibitor, Clin Pharmacol Ther
  17. Gupta, 2018, Clinical pharmacology of ixazomib: the first oral proteasome inhibitor, Clin Pharmacokinet
  18. Patel, 2017, Update on a phase II study of ixazomib with lenalidomide as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma, Blood, 130, 437
  19. Pulte, 2018, FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma, Oncologist, 23, 734, 10.1634/theoncologist.2017-0440 · DOI

Cited by

See all 237

Metadata

Authors
Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., Pluta, A., Chng, W.-J., Kaiser, M., Zweegman, S., Mateos, M.-V., Spencer, A., Iida, S., Morgan, G., Suryanarayan, K., Teng, Z., Skacel, T., Palumbo, A., Dash, A. B., Gupta, N., Labotka, R., Rajkumar, S. V., Bar, D., Basso, A., Fantl, D., He, S., Horvath, N., Lee, C., Rowlings, P., Taylor, K., Spencer, A., Cochrane, T., Kwok, F., Ramanathan, S., Agis, H., Zojer, N., Kentos, A., Offner, F., Van Droogenbroeck, J., Wu, K. L., Maiolino, A., Martinez, G., Zanella, K., Capra, M., Araújo, S., Gregora, E., Hajek, R., Maisnar, V., Pour, L., Scudla, V., Spicka, I., Abildgaard, N., Andersen, N., Jensen, B. A., Helleberg, C., Plesner, T., Salomo, M., Svirskaite, A., Delarue, R., Moreau, P., Blau, I., Goldschmidt, H., Schieferdecker, A., Teleanu, V., Munder, M., Röllig, C., Salwender, H.-J., Fuhrmann, S., Weisel, K., Duerig, J., Zeis, M., Klein, S., Reimer, P., Schmidt, C., Scheid, C., Mayer, K., Hoffmann, M., Sosada, M., Dimopoulos, A., Delimpasi, S., Kyrtsonis, M.-C., Anagnostopoulos, A., Nagy, Z., Illés, Á., Egyed, M., Borbényi, Z., Mikala, G., Dally, N., Horowitz, N., Gutwein, O., Nemets, A., Vaxman, I., Shvetz, O., Trestman, S., Ruchlemer, R., Nagler, A., Tadmor, T., Rouvio, O., Preis, M., Gay, F., Cavo, M., De Rosa, L., Musto, P., Cafro, A., Tosi, P., Offidani, M., Corso, A., Rossi, G., Liberati, A. M., Bosi, A., Suzuki, K., Iida, S., Nakaseko, C., Ishikawa, T., Matsumoto, M., Nagai, H., Sunami, K., Chou, T., Akashi, K., Takezako, N., Hagiwara, S., Eom, H. S., Jo, D.-Y., Kim, J. S., Lee, J. H., Min, C. K., Yoon, S. S., Yoon, D. H., Kim, K., Zweegman, S., Levin, M.-D., Vellenga, E., Minnema, M., Schjesvold, F., Waage, A., Haukås, E., Grosicki, S., Pluta, A., Robak, T., Marques, H., Bergantim, R., Campilho, F., Chng, W. J., Goh, Y. T., McDonald, A., Rapoport, B., Álvarez Rivas, M. A., De Arriba de La Fuente, F., González Montes, Y., Martin Sanchez, J., Mateos, M. V., Oriol Rocafiguera, A., Rosinol, L., San Miguel, J., Pérez de Oteyza, J., Encinas, C., Alegre-Amor, A., López-Guía, A., Axelsson, P., Carlson, K., Stromberg, O., Hansson, M., Hveding Blimark, C., Mueller, R., Chen, C.-C., Liu, T.-C., Huang, S.-Y., Wang, P.-N., Na Nakorn, T., Prayongratana, K., Beksac, M., Unal, A., Goker, H., Sonmez, M., Korenkova, S., Chaidos, A., Oakervee, H., Sati, H., Benjamin, R., Wechalekar, A., Garg, M., Kaiser, M., Ramasamy, K., Cook, G., Chantry, A., Jenner, M., Buadi, F., Berryman, R., & Janakiram, M.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-01
Volume
393
Issue
10168
Pages
253-264
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2904778784
Cited by
237
References
10
FWCI
19.76
Type
journal article
Language
en
Open access
bronze
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)33003-4
The paper
Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., Pluta, A., Chng, W.-J., Kaiser, M., Zweegman, S., Mateos, M.-V., Spencer, A., Iida, S., Morgan, G., Suryanarayan, K., . . . Janakiram, M. (2019). Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)33003-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.